EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT Income Before Tax
Profit after all operating and non-operating items but before income tax.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$84.88M, compared with -$45.2M a year earlier. Trailing-twelve-month income before tax was -$271.37M.
Context
- Income before tax amounted to 738.5% of revenue in FY2025, up 436.3 pp from a year earlier.
- Income before tax grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near -$84.88M or moves back toward the trailing-twelve-month quarterly average of -$67.84M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (231.68M) USD
- Year-over-year change
- -77.2%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (231.68M) | -77.2% |
| FY2024 | 2024-12-31 | (130.78M) | -84.9% |
| FY2023 | 2023-12-31 | (70.71M) | +30.8% |
| FY2022 | 2022-12-31 | (102.25M) | -75.0% |
| FY2021 | 2021-12-31 | (58.42M) | — |
Income Before Tax vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's LTM Mar 2026 income before tax of -$271.37M is the 10th highest of the 11 companies compared; the peer median is -$156.79M.
- Its year-over-year change of -85.0% is the 10th highest of 11, against a peer median of -12.6%.
- Income before tax amounts to 3563.6% of revenue for EYPT, versus a peer median of 411.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $308.21M | +226.3% | — | 43.9% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$53.06M | +10.0% | — | 55.1% |
| LTM Mar 2026 | -$81.49M | -11.6% | — | — | |
| LTM Mar 2026 | -$129.48M | -26.7% | — | — | |
| LTM Mar 2026 | -$156.46M | +5.8% | — | 17599.3% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | -$157.12M | -70.6% | — | — |
| LTM Mar 2026 | -$198.37M | +1.9% | — | 4917.6% | |
| LTM Sep 2026 | -$208.05M | -107.2% | — | — | |
| LTM Sep 2026 | -$246.76M | -13.5% | — | — | |
| LTM Mar 2026 | -$271.37M | -85.0% | — | 3563.6% | |
| LTM Mar 2026 | -$294.49M | -63.9% | — | 411.1% | |
| Peer median (excluding EYPT) | -$156.79M | -12.6% | — | 411.1% | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.94M | 41.4M | 46.02M | 43.27M | 31.37M |
| Cost of Revenue | 8.18M | 8.33M | 4.63M | 3.71M | 2.07M |
| Gross Profit | 28.76M | 33.08M | 41.39M | 39.56M | 29.31M |
| Gross Margin | 77.9% | 79.9% | 89.9% | 91.4% | 93.4% |
| Research & Development | 28.5M | 49.64M | 64.66M | 132.93M | 221.04M |
| Selling, General & Admin | 53.08M | 60.32M | 51.79M | 52.49M | 51.7M |
| Operating Expenses | 84.04M | 132.72M | 116.45M | 185.42M | 272.74M |
| Depreciation & Amortization | 2.77M | 2.45M | 464K | 1.54M | 2.31M |
| EBITDA | (50.15M) | (96.62M) | (69M) | (129.23M) | (229.34M) |
| EBITDA Margin | -135.8% | -233.4% | -149.9% | -298.6% | -731.1% |
| Operating Income | (55.28M) | (99.64M) | (75.07M) | (145.85M) | (243.43M) |
| Operating Margin | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
| Interest Income | 292K | 2.13M | 6.95M | 15.09M | 11.75M |
| Interest Expense | 5.5M | 3.19M | 1.25M | 14K | (33K) |
| Other Income / Expenses | (3.14M) | (2.62M) | 4.36M | 15.07M | 11.75M |
| Income Before Tax | (58.42M) | (102.25M) | (70.71M) | (130.78M) | (231.68M) |
| Pre-Tax Margin | -158.1% | -247.0% | -153.7% | -302.2% | -738.5% |
| Income Tax Expense | 0 | 0 | 83K | 90K | 279K |
| Net Income | (58.42M) | (102.25M) | (70.8M) | (130.87M) | (231.96M) |
| Net Margin | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
| EPS (Basic) | (2.03) | (2.74) | (1.82) | (2.32) | (3.17) |
| EPS (Diluted) | (2.03) | (2.74) | (1.82) | (2.32) | (3.17) |
| Weighted Avg Shares | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M |
| Weighted Avg Shares (Diluted) | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.